Holen Sie sich die Stockscreener-App
8.31
1.59%
0.13
Vorhandelsmarkt:
8.31
Schlusskurs vom Vortag:
$8.18
Offen:
$8.35
24-Stunden-Volumen:
216.65K
Relative Volume:
1.16
Marktkapitalisierung:
$147.39M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-38.70M
KGV:
-1.7794
EPS:
-4.67
Netto-Cashflow:
$-36.86M
1W Leistung:
-8.18%
1M Leistung:
+6.95%
6M Leistung:
-31.55%
1J Leistung:
+36.23%
1-Tages-Spanne:
$8.10
$8.595
1-Wochen-Bereich:
$8.10
$9.07
52-Wochen-Spanne:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.31 | 147.39M | 1.54M | -38.70M | -36.86M | -4.67 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf to sell equity, debt - Stock Titan
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Repeat Insider Selling Not A Positive Indicator - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit - Traders Union
[EFFECT] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
How (CRBP) Movements Inform Risk Allocation Models - Stock Traders Daily
If You Invested $1,000 in Corbus Pharmaceu (CRBP) - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Prosight Management LP Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through - openPR.com
CRBP SEC FilingsCorbus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat
Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf registration - Stock Titan
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance
Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Corbus Pharmaceuticals (CRBP) to $57 | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. 2024 Annual Report: Pipeline, Intellectual Property, Regulatory Overview, and Business Strategy - Minichart
Corbus Pharmaceuticals (CRBP) Beats Q4 EPS Estimates - GuruFocus
Corbus Pharmaceuticals (NASDAQ: CRBP) details 2025 losses, cash and key trial data - Stock Titan
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results, Highlights Promising CRB-701 and CRB-913 Clinical Updates and Extends Cash Runway Into 2028 - Minichart
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines - Traders Union
Corbus Pharmaceuticals 2025 Financials: Q4 Loss of $20.6M, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress - TipRanks
Corbus Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results - MarketBeat
Corbus Pharmaceuticals (CRBP) Eyes Breakthroughs with CRB-701 an - GuruFocus
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - Bitget
CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings - Quiver Quantitative
Corbus Pharmaceuticals: Q4 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
CRBP: Strong clinical progress and financing position support continued development into 2028 - TradingView
Corbus Pharmaceuticals (NASDAQ: CRBP) widens 2025 loss but boosts cash and pipeline progress - Stock Titan
Income Plays: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveMarket Movement Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Buyout Rumor: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesJuly 2025 Action & Real-Time Sentiment Analysis - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus (NASDAQ: CRBP) CMO offloads shares in tax-related RSU sale - Stock Titan
Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday - MarketBeat
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):